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Abstract: The Mediterranean diet (MD) may provide metabolic benefits but no systematic review to
date has examined its effect on a multitude of outcomes related to metabolic health. This systematic
review with meta-analysis (International Prospective Register of Systematic Reviews, PROSPERO;
number CRD42019141459) aimed to examine the MD’s effect on metabolic syndrome (MetSyn)
incidence, components and risk factors (primary outcomes), and incidence and/or mortality from
MetSyn-related comorbidities and receipt of pharmacologic treatment for MetSyn components and
comorbidities (secondary outcomes). We searched Pubmed, Embase, Cumulative Index to Nursing and
Allied Health Literature (CINAHL), and Web of Science for controlled trials published until June 2019,
comparing the MD with no treatment, usual care, or different diets in adults. Studies not published in
English and not promoting the whole MD were excluded. Two authors independently extracted data
and assessed risk of bias using the Cochrane Collaboration’s and Risk of Bias in non-randomised
studies (ROBINS-I) tools. Reporting followed the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines. Random-effects meta-analyses, subgroup analyses and
meta-regressions were performed, and heterogeneity was quantified using the I2 statistic. We identified
2654 reports and included 84 articles reporting 57 trials (n = 36,983). In random effects meta-analyses,
the MD resulted in greater beneficial changes in 18 of 28 MetSyn components and risk factors
(body weight, body mass index, waist circumference, systolic and diastolic blood pressure, glucose,
insulin, homeostatic model assessment of insulin resistance (HOMA-IR) index, total-, low-density
lipoprotein (LDL)- and high-density lipoprotein (HDL)-cholesterol, triglycerides, alanine transaminase,
hepatic fat mass, C-reactive protein, interleukin-6, tumour necrosis factor-a, and flow-mediated
dilatation) and lower risk of cardiovascular disease incidence (risk ratio (RR) = 0.61, 95% confidence
intervals (CI) 0.42–0.80; I2 = 0%), and stroke (RR = 0.67, 95% CI 0.35–0.98; I2 = 0%). Only six
studies reported effects on pharmacotherapy use, and pooled analysis indicated no differences
between diet groups. Lack of consistency in comparator groups and other study characteristics
across studies resulted in high heterogeneity for some outcomes, which could not be considerably
explained by meta-regressions. However, a consistent direction of beneficial effect of the MD was
observed for the vast majority of outcomes examined. Findings support MD’s beneficial effect
on all components and most risk factors of the MetSyn, in addition to cardiovascular disease and
stroke incidence. More studies are needed to establish effects on other clinical outcomes and use of
pharmacotherapy for MetSyn components and comorbidities. Despite the high levels of heterogeneity
for some outcomes, this meta-analysis enabled the comparison of findings across studies and the
examination of consistency of effects. The consistent direction of effect, suggesting the MD’s benefits
on metabolic health, supports the need to promote this dietary pattern to adult populations.
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1. Introduction
The prevalence of the metabolic syndrome (MetSyn) is increasing worldwide [1], with approximately
one-quarter of the world’s population estimated to present with the syndrome [2]. MetSyn is associated
with increased risk of comorbidities, including cardiovascular disease (CVD) [3], type 2 diabetes [4],
non-alcoholic fatty liver disease (NAFLD) [5], and several forms of cancer [6]. Various therapies are
routinely prescribed for some of these comorbidities, such as statins for primary [7], and coronary artery
bypass grafting (CABG) or percutaneous coronary intervention (PCI) for secondary [8], prevention of
CVD. Despite these therapies, dietary modifications continue to have an imperative role in MetSyn
and MetSyn-related comorbidity prevention and management [9].
The Mediterranean diet (MD) is characterised by high intake of olive oil and plant foods
(fruits, vegetables, legumes, nuts and non-refined cereals), low-to-moderate intake of dairy products,
fish and poultry, moderate intake of alcohol, and low intake of red meat and sweets [10]. Two meta-analyses
showed that the MD is associated with decreased risk of MetSyn [11] and produces favourable changes
in MetSyn components [11,12]. These prior meta-analyses did not, however, report on other MetSyn
risk factors, such as obesity markers and markers of inflammation, oxidative stress, insulin resistance,
endothelial function and NAFLD, which would be important to establish the MD’s effect on all
factors related to the MetSyn. The MD has also been linked to decreased risk of MetSyn-related
comorbidities [13–16], but its effect on use of pharmacologic treatment for MetSyn components and
comorbidities has not yet been examined. In addition, some earlier meta-analyses examining the
effect of the MD on different health outcomes used questionable definitions of what constitutes this
dietary pattern, or included studies where the dietary intervention only advised on the consumption
of specific foods that are part of the MD [17,18], thus introducing biased conclusions. Overall, no study
to date has systematically assessed and synthesised the evidence on the effect of the whole MD on
MetSyn incidence and its components and risk factors, concurrently to MetSyn-related comorbidities
and changes in use of pharmacotherapy for the treatment of MetSyn components and comorbidities.
This is essential for establishing the MD’s effect on metabolic health [1].
To address this gap, and answer the research question ‘What is the effect of the MD on metabolic
health in adults?’, we conducted a systematic review and meta-analysis of evidence from controlled trials
of the effect of the MD, compared to no treatment, usual care, or different diets, on MetSyn incidence,
MetSyn components (used in defining the MetSyn), and additional risk factors (primary objectives).
Secondary objectives were incidence and/or mortality from MetSyn-related comorbidities and
intermediate markers of these comorbidities, as well as changes in use of pharmacologic treatment
for MetSyn components and comorbidities. This work updates and broadens the scope of earlier
meta-analyses [11–15] and applies rigorous methodology to evaluate the available evidence.
2. Materials and Methods
The protocol for this systematic review and meta-analysis was registered with the
International Prospective Register of Systematic Reviews (PROSPERO, number CRD42019141459).
Reporting followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA)
guidelines (Supplementary Materials Table S1) [19].
2.1. Data Sources and Searches
The systematic search Supplementary Materials Table S2) included subject headings and keyword
terms for the MD, MetSyn, and related comorbidities, and was conducted in PubMed, Embase, Web of
Science Core Collection, and CINAHL (Cumulative Index to Nursing & Allied Health Literature),
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from inception until 17 June 2019. The search was limited to papers published in English. Reference lists
of eligible papers were also hand-searched.
2.2. Study Selection
Studies were included if they were controlled trials (randomised and non-randomised) reporting
pre- and post-intervention findings, and: (1) Participants were adults who were non-pregnant,
non-lactating, and free of conditions that might affect their ability to eat certain foods; (2) the
intervention promoted the whole MD or MD-style diet, with or without physical activity (as long as
physical activity was equally promoted in the control group), and; (3) the MD was compared with
no treatment, usual care, or advice to follow a different diet. Eligible studies focused on outcomes
commonly assessed in everyday clinical practice in order to enhance relevance and translational
potential to healthcare practitioners. Studies were included if they reported at least one of the
following: (1) MetSyn incidence; (2) MetSyn components (waist circumference, blood pressure,
and blood concentrations of high-density lipoprotein (HDL)-cholesterol, triglycerides, and glucose),
and additional risk factors (anthropometric and biochemical markers, markers of oxidative stress,
inflammation, endothelial function and insulin resistance); (3) incidence and/or mortality from
MetSyn-related (type 2 diabetes, NAFLD, CVDs and cancer), and/or intermediate (e.g., pre-diabetes)
comorbidities, and; (4) outcomes related to pharmacologic treatment for MetSyn components and the
aforementioned comorbidities.
The titles and abstracts of identified papers were independently screened by two reviewers
and the full text of all relevant papers was reviewed against the inclusion and exclusion criteria
(Table 1; Supplementary Materials Table S3). Disagreements were resolved through discussion. Figure 1
illustrates the literature search and study selection process.
Table 1. Criteria for inclusion of studies.
Parameter Criterion
Population Adults aged ≥18 years
Intervention Mediterranean or Mediterranean-style diet
Comparator No treatment, usual care, or advice to follow a different diet
Outcome
(1) Metabolic syndrome incidence;
(2) Metabolic syndrome components and additional risk factors (anthropometric and
biochemical markers, markers of oxidative stress, inflammation, endothelial function
and insulin resistance);
(3) Incidence and/or mortality from metabolic syndrome-related (type 2 diabetes,
non-alcoholic fatty liver disease, cardiovascular diseases, such as coronary heart
disease, stroke and heart failure, and cancer) and/or intermediate (e.g., pre-diabetes)
comorbidities, and;
(4) Outcomes related to medication/therapy received for metabolic syndrome
components and metabolic syndrome-related comorbidities
Study design Controlled trials
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Figure 1. Flow diagram of literature search and study selection.
2.3. Data Extraction and Quality Assessment
Data extracted included study and population characteristics, and outcomes, including baseline,
post-intervention, and follow-up values, as well as between-group changes in outcomes, where available.
Studies were assessed as having low, high, or unclear risk of bias using the Cochrane risk of bias
tool for randomised controlled trials [20]. For papers reporting on non-randomised controlled trials,
the ROBINS-I (Risk of Bias in Non-randomised Studies of Interventions) tool was used to assess risk
of bias [21]. Data were extracted and risk of bias was assessed independently by two reviewers into
a piloted Excel form. Disagreements were resolved through discussion or third-party adjudication.
Authors were contacted if clarification on any aspect of their reporting was required.
2.4. Data Synthesis and Analysis
For each included paper, effect sizes were summarised for each outcome by: (1) Calculating
risk ratios (RRs) or hazard ratios (HRs) from the reported data (if these were not reported already),
and; (2) calculating the mean difference between the intervention and control condition from the
pre-intervention to the post-intervention period (and, where available, from the pre-intervention to the
follow-up period). Data on outcomes were transformed, where applicable, into the same measurement
units using standard conversion factors, to allow comparisons between studies, and a pooled analysis.
If an included paper reported multiple outcomes of interest to the current review, each outcome was
evaluated and reported independently. If an eligible and included paper reported on the follow-up
measurements of an intervention study (for which the post-intervention results were reported in
a separate, also included, paper), and both papers reported on the same outcome, findings from the
follow-up were reported in the qualitative synthesis, but only the post-intervention findings were
meta-analysed. If a paper was based on a study that had two comparison groups, we included the
control condition where another diet was promoted (instead of usual care, no treatment, or usual diet).
As heterogeneity between studies was expected, a random-effects meta-analysis was used to
su marise intervention effect estimates, expressed as RRs, HRs, or mean differences (inverse variance)
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with 95% confidence intervals (CIs). Heterogeneity between studies was assessed using the I2 statistic,
with values >50% indicating substantial heterogeneity [22]. Papers reporting outcomes as median
(range) or for which an appropriate combination of means, standard deviations, standard errors, or CIs
for the outcomes of interest was not available (for example, to calculate the standard deviation of the
difference between time points), were not included in the meta-analysis [23]. Where appropriate, a priori
subgroup analyses were conducted to examine whether supplementing dietary advice on the MD with
MD foods would result in greater effectiveness, compared to advice alone. This might have important
translational implications, particularly in non-Mediterranean countries like the United States, where the
MD is recommended within the dietary guidelines [24], but it is uncertain if Americans would find it
easy to follow [25]. If the MD was suggested to be an effective strategy to improve MetSyn outcomes
but barriers to using MD foods indeed obstructed dietary adherence, health systems might need to
consider ‘prescribing’ MD foods to help adults adopt this diet for greater effects. However, there is
no evidence to date to support this. Potential sources of heterogeneity across studies were further
assessed using meta-regression, by comparing results from studies grouped according to study-level
characteristics, including location (posthoc, Mediterranean vs. not), health status (posthoc, healthy vs.
unhealthy at baseline), intervention duration (a priori, <6 m and ≥6 m, categories created based on data
available), sample size (a priori, <150 and ≥150 participants, categories created based on data available),
intervention diet (posthoc, MD vs. MD and another dietary component, e.g., a reduced-energy
MD), and type of comparator (posthoc, no treatment; low-fat diet; reduced energy, low-fat diet;
low-fat, high-carbohydrate diet; healthy diet or dietary guidelines, and; the National Cholesterol
Education programme diet). Subgroup analyses were only conducted for outcomes with at least
10 studies included [26].
As the inclusion of non-randomised trials might introduce bias, particularly relating to
confounding [21], a posthoc sensitivity analysis was conducted to examine the effect of excluding
findings from these trials from the analysis. Further sensitivity analyses were conducted after exclusion
of cross-over trials (a priori) and studies with ≥1000 participants (posthoc). Due to the low number
of studies reporting on MetSyn incidence and the secondary outcomes, subgroup and sensitivity
analyses were conducted only for MetSyn components and risk factors. STATA 13.0 (StataCorp LP,
College Station, TX, USA) was used to conduct the meta-analyses and meta-regressions and to assess
evidence of publication bias by visual evaluation of funnel plots and Egger tests (the statistical code is
available from the authors upon request). Review Manager 5.3 was used to create risk of bias figures.
3. Results
Eighty-four papers (representing 57 unique trials) were included in the qualitative synthesis
(Figure 1) [27–111], reporting on 36,983 participants (mean age 55.5 ± 11.5 years, range 21.2–71.0 years).
The list of the 116 excluded papers can be found in Supplementary Materials Table S4.
3.1. Study Characteristics
Of the 84 papers (Supplementary Materials Table S5), 8 reported non-randomised controlled trials,
8 had a cross-over design, 43 were based in Mediterranean regions, and 49 on studies that supplemented
advice with MD foods (Supplementary Materials Table S6). Sample sizes ranged from 11 [77] to
7447 [51,53]. Thirteen papers reported on studies that recruited healthy adults. Intervention duration
varied from 10 days [65] to 7 years [78,79]. Thirty-six papers reported on studies where both the
intervention and control groups received physical activity instructions. The dietary component of
the intervention received by the intervention groups comprised of education on: The MD (n = 55);
an energy-controlled MD (n = 1), a low-energy MD (n = 15), and a low-energy MD (if required) (n = 3);
a low-energy, low-carbohydrate MD (n = 4); an Indo-MD (n = 2); and a low-glycaemic index MD (n = 2).
The control groups received no treatment (n = 11); usual care (n = 1); and received advice to change
their dietary habits in 72 papers (low-fat diet, n = 27; reduced energy low-fat diet, n = 10; low-fat,
high-carbohydrate diet, n = 2; healthy eating, prudent diet, or general dietary guidelines, n = 13;
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usual Swedish diet, n = 1; usual German diet, n = 1; a north American diet, n = 2; reduced energy
central European diet, n = 2; a high-fat or high-saturated fat diet, n = 2; a reduced energy and very low
carbohydrate diet, n = 1; the National Cholesterol Education programme diet, n = 3; a low-glycemic
index diet, n = 2; a vegan diet, n = 1; a reduced energy vegetarian diet, n = 1, and; a reduced energy
prudent diet, n = 2) (Supplementary Materials Table S5).
Compliance to the intervention was assessed via conventional dietary assessment methods
(e.g., food frequency questionnaires, 24-h recalls, food diaries, short adherence questionnaires,
or a combination of these) in 53 papers; a combination of dietary assessment methods and biomarkers
in 21 papers; compliance checklists in three papers; diet history interviews in two papers, and;
biomarkers only in one paper. Three studies [72,73,102] did not report the method for assessing
compliance while one study used supervision to assess compliance to treatment [83].
3.2. Metabolic Syndrome Incidence, Components and Risk Factors
Only one paper (reporting on two comparisons in 5801 participants) [31] examined the effect
of the MD on MetSyn incidence risk; no between-group differences were found when the MD was
supplemented with olive oil (control vs. MD: HR 1.10; 95% CI, 0.94–1.30), nor when it was supplemented
with nuts (control vs. MD: 1.08; 0.92–1.27), compared to a low-fat control diet. The qualitative synthesis
findings on MetSyn risk factors (for papers and/or outcomes not included in the pooled analysis) are
presented in Supplementary Materials Tables S7–S9. The pooled analysis (Table 2 and Supplementary
Materials Figures S1–S28) showed that the MD had a greater beneficial effect, compared to a control
condition, on 18 of 28 MetSyn risk factors (body weight, body mass index, waist circumference,
systolic and diastolic blood pressure, glucose, insulin, homeostatic model assessment of insulin
resistance (HOMA-IR) index, total-, low-density lipoprotein (LDL)- and HDL-cholesterol, triglycerides,
alanine transaminase, hepatic fat mass, C-reactive protein, interleukin-6, tumor necrosis factor-a,
and flow-mediated dilatation), including all MetSyn components. There was substantial between-study
heterogeneity for most of these meta-analyses, with null heterogeneity found only in four meta-analyses
involving very few studies (Table 2).
Table 2. Effect of the Mediterranean diet on anthropometric, blood pressure, biochemical, insulin resistance,
oxidative stress, inflammatory, and endothelial function markers related to the metabolic syndrome *.
Outcome No. of Studies No. ofParticipants
Effect Estimate
(MD, 95% CI) p-Value I
2
Anthropometric markers
Body weight (kg) 40 12,571 −1.72 (−2.40, −1.05) <0.001 98.6%
Body mass index (kg/m2) 37 5679 −0.41 (−0.71, −0.10) 0.010 98.6%
Waist circumference (cm)
(MetSyn component) 27 9690 −1.47 (−2.54, −0.39) 0.007 99.6%
Total fat mass (kg) 9 963 −0.47 (−1.53, 0.60) 0.389 85.1%
Total body fat (%) 8 661 −0.12 (−1.60, 1.37) 0.878 89.7%
Blood pressure (MetSyn component)
Systolic blood pressure (mm Hg) 27 4930 −1.34 (−2.00, −0.67) <0.001 93.6%
Diastolic blood pressure (mm Hg) 27 4930 −0.81 (−1.30, −0.32) 0.001 92.8%
Biochemical and insulin resistance markers
Glucose (mg/dL)
(MetSyn component) 31 3662 −2.98 (−4.54, −1.42) <0.001 98.1%
Insulin (µU/mL) 20 2184 −0.94 (−1.72, −0.16) 0.019 97.2%
HOMA-IR index 18 2098 −0.42 (−0.70, −0.15) 0.003 97.7%
HbA1c (%) 18 869 −0.15 (−0.41, 0.12) 0.274 81.3%
Total cholesterol (mg/dL) 37 4603 −5.70 (−9.96, −1.43) 0.009 98.6%
LDL-cholesterol (mg/dL) 29 3633 −8.24 (−13.50, −2.99) 0.002 99.6%
HDL-cholesterol (mg/dL)
(MetSyn component) 36 4433 1.30 (0.38, 2.21) 0.005 98.1%
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Table 2. Cont.
Outcome No. of Studies No. ofParticipants
Effect Estimate
(MD, 95% CI) p-Value I
2
Triglycerides (mg/dL)
(MetSyn component) 38 4658 −12.30 (−15.60, −8.99) <0.001 94.8%
Non-HDL-cholesterol (mg/dL) 2 584 −1.39 (−19.40, 16.61) 0.880 42.3%
Total:HDL-cholesterol ratio 6 670 −0.83 (−2.67, 1.01) 0.378 99.6%
Homocysteine (µmol/L) 2 171 −0.04 (−0.61, 0.53) 0.882 0.0%
AST (UI/L) 3 193 −3.44 (−7.56, 0.68) 0.102 97.7%
ALT (UI/L) 8 729 −5.66 (−9.44, −1.87) 0.003 97.3%
GGT (UI/L) 7 393 −2.51 (−5.38, 0.35) 0.086 63.7%
Hepatic fat mass (%) 3 224 −2.80 (−5.52, −0.08) 0.044 79.0%
Oxidative stress markers
Oxidized LDL-cholesterol (U/L) 2 970 4.38 (−16.49, 25.25) 0.681 97.7%
Inflammatory markers
C-reactive protein (mg/L) 13 1071 −0.77 (−1.14, −0.39) <0.001 92.6%
Interleukin-6 (pg/mL) 4 261 −0.61 (−0.93, −0.30) <0.001 0.0%
Adiponectin (µg/mL) 4 546 0.76 (−1.16, 2.67) 0.438 70.4%
Tumor necrosis factor-a (pg/mL) 2 283 −0.81 (−1.03, −0.60) <0.001 0.0%
Markers of endothelial function
Flow-mediated dilatation (%) 3 206 1.49 (0.61, 2.37) <0.001 0.0%
ALT, alanine transaminase; AST, aspartame transaminase; CI, confidence intervals; GGT, gamma glutamyl
transferase; HDL, high-density lipoprotein cholesterol; HbA1c, glycosylated hemoglobin; HOMA-IR, homeostatic
model assessment of insulin resistance; LDL, low density lipoprotein cholesterol; MD, mean difference; MetSyn,
metabolic syndrome. * Findings are based on random-effects meta-analysis (inverse variance). I2 represents the
magnitude of heterogeneity.
3.3. Metabolic Syndrome-Related Comorbidities
The MD resulted in lower risk of CVD (RR 0.61; 95%CI, 0.42–0.80; I2 = 0%; two studies), and stroke
incidence (0.67; 0.35–0.98; I2 = 0%; two studies), compared to a control condition. There were no
between-group differences in CVD mortality (0.72; 0.43–1.01; I2 = 0%; three studies), sudden cardiac
death (0.45; −0.15–1.04; I2 = 0%; two studies), heart failure incidence (0.69; 0.08–1.30; I2 = 59.4%;
two studies), type 2 diabetes incidence (0.81; 0.61–1.02; I2 = 0%; two studies), and fatal (0.68; 0.23–1.12;
I2 = 0%; two studies), and non-fatal MI (0.45; −0.001–0.900; I2 = 0%; two studies), despite effect estimates
in the expected direction (Table 3 and Supplementary Materials Figures S29–S36). Findings from
individual studies not included in the pooled analysis suggested a beneficial effect of the MD in reducing
the risk of the incidence of angina (RR 0.60; 0.40–0.91; 1000 participants), pre-diabetes (0.19; 0.10–0.35;
406 participants), and breast cancer (HR 0.49; 95% CI, 0.25–0.94; 4152 participants), but not stroke
mortality (RR 0.67; 0.11–4.02; 1000 participants), MI incidence (HR 0.80; 0.53–1.21; 7447 participants),
or overall cancer incidence (RR 1.00;0.14–7.10; 1000 participants) or mortality (RR 1.00; 0.06–16.01;
1000 participants) (Supplementary Materials Table S9).
Nutrients 2020, 12, 3342 8 of 21
Table 3. Effect of the Mediterranean diet on metabolic syndrome-related comorbidities and pharmacologic treatment for metabolic syndrome components and related
comorbidities *.
Outcome No. of Studies Intervention Control Effect Estimate (RR, 95% CI) p-Value I2
Events Total Events Total
Metabolic Syndrome-related comorbidities
CVD mortality 3 90 5503 96 2955 0.72 (0.43, 1.01) 0.090 0.0%
CVD incidence 2 119 703 201 703 0.61 (0.42, 0.80) <0.001 0.0%
Sudden cardiac death 2 15 703 34 703 0.45 (−0.15, 1.04) 0.142 0.0%
Stroke incidence 2 88 5496 71 2951 0.67 (0.35, 0.98) <0.001 0.0%
Heart failure incidence 2 73 5470 67 2933 0.69 (0.08, 1.30) 0.300 59.4%
Non-fatal myocardial infarction 2 26 801 60 804 0.45 (−0.001, 0.900) 0.051 0.0%
Fatal myocardial infarction 2 30 703 44 703 0.68 (0.23, 1.12) 0.090 0.0%
Type 2 diabetes incidence 2 207 2598 144 1349 0.81 (0.61, 1.02) 0.051 0.0%
Pharmacotherapy
Use of blood pressure lowering drugs 3 2444 3299 1130 1657 0.99 (0.96, 1.02) 0.550 0.0%
Use of lipid-lowering agents 2 1552 2738 602 1090 1.01 (0.95, 1.08) 0.690 0.0%
Use of anti-platelet therapy 2 818 2738 338 1090 0.99 (0.90, 1.08) 0.830 0.0%
Use of insulin 2 271 2738 109 1090 0.99 (0.78, 1.20) 0.890 0.0%
Use of oral antidiabetic agents 3 1112 2846 520 1197 0.83 (0.58, 1.09) 0.230 64.2%
CVD, cardiovascular disease; RR, risk ratio. * Findings are based on random-effects meta-analysis (inverse variance). I2 represents the magnitude of heterogeneity.
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3.4. Pharmacotherapy
Six studies reported on the effect of the MD on pharmacologic treatment of MetSyn components
and/or related comorbidities [47,48,53,62,68,91,93]. In the pooled analysis (Table 3 and Supplementary
Figures S37–S41), there were no differences between the MD and a control condition in the need for
blood pressure medication (RR 0.99; 95% CI, 0.96–1.02; I2 = 0%; three studies), lipid-lowering agents
(1.01; 0.95–1.08; I2 = 0%; two studies), anti-platelet therapy (0.99; 0.90–1.08; I2 = 0%; two studies),
insulin (0.99; 0.78–1.20; I2 = 0%; two studies), or oral anti-diabetic agents (0.83;0.58–1.09; I2 = 64.2%;
three studies). Evidence from one study in 1000 participants suggested a beneficial effect of the
MD, compared to a control condition, on the use of nitrates (RR 0.67; 95% CI, 0.54–0.83), β-blockers
(0.55; 0.37–0.80), and disopyramide (0.28; 0.13–0.60) [93]. In the one study reporting a beneficial effect
of the MD on hyperglycaemic drug use (HR 0.63; 95% CI, 0.50–0.81) [47] in 215 participants, this effect
was maintained at follow-up (0.68; 0.50–0.89) [48] (Supplementary Table S10).
3.5. Quality Assessment
Supplementary Materials Figure S42 summarises the included randomised controlled trials’
risk of bias assessment. Overall, there was a low risk of bias for selective outcome reporting and
random sequence generation. Acceptable participant retention and/or reporting of attrition bias were
considered to be achieved by 50% of papers. Risk of bias for blinding of participants and personnel,
a challenging task in behaviour change interventions, was evaluated as high for the vast majority
of papers. The majority of papers were also considered to have high risk of other bias, due to e.g.,
the self-reported nature of assessing intervention compliance. Approximately 50% of papers did not
report whether allocation was concealed and >50% whether assessment of outcomes was blinded.
Across the 72 papers, risk of bias was considered low, unclear, and high for 41%, 26%, and 33% of the
domains, respectively.
Visual evaluation of the funnel plots (Supplementary Materials Figures S43–S83) defined some
asymmetry in some outcomes, but the Egger tests suggested small study effects only for body mass
index (bias, −5.49; standard error (SE), 1.14; p < 0.001), waist circumference (bias, −6.77; SE, 2.85;
p = 0.026), systolic (bias, 1.82; SE, 0.83; p = 0.039) and diastolic blood pressure (bias, 2.00; SE, 0.73;
p = 0.011), total cholesterol (bias, 4.86; SE, 1.32; p = 0.001), and triglyceride concentrations (bias, 2.51;
SE, 0.65; p < 0.001). For other outcomes, Egger tests did not suggest publication bias. Based on the
ROBINS-I tool, two non-randomised controlled trials were evaluated as having serious risk of bias
and one as having critical risk of bias, whereas there was no information on which to base a judgment
about risk of bias in remaining studies (Supplementary Materials Table S11).
3.6. Subgroup Analyses
The subgroup analyses based on meta-regression are presented in Supplementary Materials
Table S12. There was a greater effect of the MD compared with control diets on body weight (−2.82 vs.
−0.41 kg; p = 0.011; p-heterogeneity < 0.001) and body mass index (−0.70 vs. 0.11 kg/m2; p < 0.001;
p-heterogeneity < 0.001) when interventions were not supplemented with foods, compared with the
subgroups of studies that provided foods. There was also a greater effect of the MD on blood glucose
when studies did not supplement foods (−5.81 vs. −0.20 mg/dL; p = 0.016; p-heterogeneity < 0.001),
were conducted in Mediterranean, compared to non-Mediterranean, countries (−5.47 vs. −0.31 mg/dL;
p = 0.025; p-heterogeneity < 0.001), and when intervention duration was ≥6 months, compared to
<6 months (−6.97 vs. −0.18 mg/dL; p = 0.002; p-heterogeneity < 0.001). A greater reduction in
body weight (−2.97 vs. −1.09 kg; p = 0.043; p-heterogeneity < 0.001) and body mass index (−0.63 vs.
−0.19 kg/m2; p = 0.035; p-heterogeneity < 0.001) was also observed in studies where the MD was
promoted alongside another dietary component, compared to alone. Food supplementation accounted
for approximately 18%, 55%, 17%, and 19% of the heterogeneity observed for body weight, body mass
index, diastolic blood pressure, and blood glucose, respectively, whereas intervention duration
Nutrients 2020, 12, 3342 10 of 21
accounted for 27% and 19% of the variance in blood glucose and C-reactive protein concentrations,
respectively. However, high levels of within-group heterogeneity were observed for most subgroups,
suggesting these findings might be uncertain.
3.7. Sensitivity Analyses
Sensitivity analysis, by excluding the non-randomised controlled trials [35,80,85–87,101,102],
was conducted for 18 MetSyn components and risk factors (Supplementary Materials Table S13).
Findings and heterogeneity levels largely remained unchanged, but were attenuated for waist
circumference (−0.94 cm; 95% CI, −2.08–0.19; I2 = 100%; 24 studies), HDL-cholesterol (0.93 mg/dL;
−0.06–1.92; I2 = 98%; 31 studies), and alanine transaminase (−2.39 UI/L; −5.77–0.99; I2 = 96%; 7 studies),
whereas reduction of glycosylated hemoglobin (HbA1c) was larger in the MD, compared to a control
condition (−0.29%; −0.40–−0.18; I2 = 4%; 5 studies). In addition, results were largely similar when
cross-over trials [29,35,65,77,88,97,108,109] were excluded, although this attenuated the between-group
difference in insulin concentrations (−0.77 µU/mL; 95%CI, −1.71–0.17; I2 = 97%; 15 studies) and hepatic
fat mass (−2.04%; −5.95–1.88; I2 = 86%; 2 studies). Results remained unchanged when studies with
≥1000 participants [31,51,62,93,103] were excluded from the analyses. Excluding non-randomised
trials reduced the levels of heterogeneity for HbA1c from 78% to 4%, but otherwise heterogeneity
remained substantial (Supplementary Materials Table S13).
4. Discussion
This systematic review of 84 papers and 57 controlled trials aimed to evaluate the effect of the MD,
compared to usual care, no treatment, or a different diet, on MetSyn incidence, MetSyn components
and risk factors, in addition to related comorbidity outcomes and treatment for these health outcomes.
To our knowledge, this is the most comprehensive list of MetSyn-related outcomes systematically
assessed. We moved beyond evaluating effects on the factors used to define the MetSyn, to examining
additional risk factors, such as markers of obesity, oxidative stress, inflammation, endothelial function,
insulin resistance, and NAFLD, allowing for a more comprehensive metabolic health assessment.
We found no evidence that the MD leads to lower incidence of the MetSyn, but there were greater
beneficial changes in the majority of the MetSyn factors examined, in addition to lower risk of CVD
incidence, and incidence of stroke. The qualitative synthesis also suggested that the MD lowers the risk
of angina, pre-diabetes, and breast cancer, and results in lower need for the use of hyperglycaemic drugs,
nitrates, β-blockers, and disopyramide, albeit from a small number of studies. There was no evidence
for an effect on other comorbidity endpoints or use of other medications. Nevertheless, effect estimates
for most of these outcomes favoured the MD. However, findings from this work should be viewed
in light of the small number of studies for some outcomes, the considerable bias identified within
a proportion of the included studies, and the substantial between-study heterogeneity found for most
pooled analyses.
To our knowledge, this is the first study to examine the effect of the MD on MetSyn incidence.
Results from only one study in 5801 participants showed no evidence of reduction in incidence risk [31].
An earlier meta-analysis of two clinical trials showed a 20% reduced risk of MetSyn presence [11],
but this referred to studies reporting MetSyn prevalence at post-intervention, rendering comparisons
with our findings challenging. More studies are therefore needed to establish the MD’s effect on
MetSyn incidence. We also found that the MD results in beneficial changes in all components defining
the MetSyn, in addition to the majority of the additional risk factors assessed. There was no evidence
of an effect for other risk factors, despite effect estimates favouring the MD over a control treatment.
These findings are supported by earlier meta-analyses (in 4133 and 16,689 participants), which showed
a beneficial effect of the MD in the components defining the MetSyn [11,12]. Comparable to our findings,
another meta-analysis in 2300 participants showed that the MD results in greater beneficial changes in
several markers of inflammation and endothelial function, including C-reactive protein, interleukin-6,
and flow-mediated dilatation [112]. Our review extends knowledge from these meta-analyses,
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incorporating more recent studies in 36,983 participants and evaluating, for the first time, the effect of
the MD on markers of oxidative stress and NAFLD, demonstrating greater beneficial changes of the
MD, compared to a control condition, in alanine transaminase concentrations, and hepatic fat mass,
albeit from a small number of studies. More studies are therefore needed to examine the effect of the
MD on these biomarkers of metabolic health.
It is noteworthy that, consistent with an earlier meta-analysis of clinical trials in 3436 participants
reporting a decrease in body weight of 1.75 kg (95% CI −2.86–−0.64) [113], our analysis of
12,751 participants showed a similar finding (−1.72 kg; −2.40–−1.05; I2 = 98.6%), although results were
slightly attenuated when the MD was promoted alone (−1.09 kg; p = 0.016) vs. alongside other dietary
components, such as energy restriction (−2.97 kg; p < 0.001). The impact that adhering to the MD
would have on caloric intake and body weight, stemming from e.g., the MD’s recommendation to have
olive oil with every meal and nuts every day [10], has been documented as an important barrier to
adhering to this dietary pattern by both healthy adults [114], and adults at high risk of developing
CVD [115]. Given absence of evidence suggesting the MD promotes obesity, health practitioners
should therefore consider not abstaining from promoting the MD to their patients over concerns that it
is ‘fattening’. Even though the MD is suggested to be transferable [116], whether non-Mediterranean
populations could adhere to this dietary pattern remains to be established [25]. Qualitative studies in
the United Kingdom have suggested that cultural differences, cost, lack of cooking skills, and time could
hinder acceptability and adherence to the MD [114,115]. Similar qualitative research and feasibility
studies are needed in other non-Mediterranean countries, such as the United States, a country where
a Mediterranean-style diet is recommended as a USDA-approved food pattern by the 2015 US Dietary
Guidelines [24]. This will help explore facilitators and barriers to the MD, as well as the perceived
intervention characteristics that would be acceptable to the diverse US population, before embarking
on large randomised controlled trials testing the diet’s effectiveness on metabolic health.
Concomitant to concerns about the type of support that Americans and other non-Mediterranean
populations might need to adopt the MD, are issues regarding the potential need to provide MD
foods for free to facilitate dietary adherence. Our findings showed, for the first time, that while
supplementing dietary advice with foods from the MD led to beneficial changes in some MetSyn
factors, subgroup analyses revealed there is no evidence it leads to greater health benefits beyond those
obtained by advice alone. Indeed, studies not providing foods led to greater changes in body weight,
body mass index, and blood glucose concentrations, compared to those supplementing MD advice
with foods. It might have been that participants consumed supplemented foods as an addition to,
instead of substituting them for other foods in their diet, which might have affected health outcomes.
However, this is challenging to confirm due to the varying levels of reporting of compliance with the
dietary prescriptions across the reviewed studies. Also, the types and amounts of foods provided
in the reviewed studies varied widely, from providing some components of the MD (e.g., olive oil,
nuts, legumes, fish) to the majority [29,73,83,88], or all meals [61,85,86]. It is not suggested that
providing MD foods is void of benefit. In certain clinical situations, supplementation could be integral
in a patient’s care plan formulated under shared processes. However, more studies are needed to
delineate nuanced impacts of food supplementation in these unique populations and socioeconomic
settings. Head-to-head trials addressing these questions are thus needed.
Our results are overall consistent with earlier meta-analyses showing that the MD reduces risk
of CVD, stroke [117], and breast cancer [15] incidence, but not heart failure [117]. In contrast to
other reviews, we found no evidence of an effect of the MD on CVD mortality [118], and type 2
diabetes [119], while we additionally demonstrated a reduction in angina and pre-diabetes risk,
albeit from one study. Comparisons between the current and earlier pooled analyses are hindered
by different search strategies, study inclusion and exclusion criteria, and differing MD definitions.
Nevertheless, we reported a 39% and 33% reduction in CVD and stroke incidence risk, respectively.
This is a higher reduction compared to that demonstrated by statins for the primary prevention of CVD
(RR 0.75; 95% CI, 0.70–0.81), and stroke (RR 0.78; 95% CI 0.68–0.89) [7], and for the secondary prevention
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of CVD in patients with type 2 diabetes (RR 0.85; 95% CI 0.79–0.91) [120]. The level of risk reduction
demonstrated by our findings is comparable to the reduction in stroke incidence risk exhibited by
PCI, when compared to CABG (RR 0.64; 95% CI, 0.48–0.85) [8]. It has also been shown that the MD
reduces major vascular event risk by 37% (RR 0.63; 95% CI, 0.53–0.75) [117], whereas PCI, compared to
CABG, increases this risk by 36% (RR 1.36; 95% CI 1.16–1.60) [8]. Although these comparisons should
be interpreted with caution, they suggest that the MD could be an adjunctive therapeutic means for
the primary and secondary prevention of CVD. However, randomised controlled trials comparing the
MD versus statins and/or secondary prevention treatments are needed to confirm this hypothesis.
To our knowledge, no other review has systematically evaluated the MD’s effect on the need for
pharmacologic treatment for MetSyn components and related comorbidities. Only six studies reported
on the changes of the need for treatments, and of these, only one reported treatment as a primary
outcome, showing that the MD reduced the need for antihyperglycemic drug therapy at four years [47];
maintained at the six-year follow-up [48]. All other studies reported changes in the proportion of
participants requiring treatment post-intervention as a secondary outcome, and, thus, may not have
had sufficient statistical power to detect any effects. Nevertheless, the beneficial effects of the MD
on the use of nitrates, β-blockers, and disopyramide, albeit from one study in 1000 participants [93],
as well as the results by Esposito et al. in 215 participants [47,48], suggest that the MD might be
a promising means of reducing the economic burden that pharmacotherapy poses to patients and
national health systems globally. However, more well-designed studies, using treatment for MetSyn
components and related comorbidities as a primary outcome, are needed to ascertain this.
Strengths and Limitations
Strengths of the current review include the use of rigorous methodology, according to
current guidelines of conduct and reporting [19,20], to systematically evaluate, for the first time,
the effect of the MD on a wide range of outcomes implicated in metabolic health. In contrast to
earlier meta-analyses [17,18], we evaluated studies promoting the whole MD. We included both
randomised and non-randomised controlled trials to obtain an indication of all intervention effects;
however, only eight of the 84 reports involved non-randomised designs, and results following the
sensitivity analysis largely remained unchanged after the exclusion of these. This work also has
limitations. Despite a comprehensive search strategy, we included papers published in English only
and we cannot exclude the possibility that eligible studies might not have been included due to
the search terms. There were few studies identified and/or events documented for some outcomes.
This reflects the challenge of conducting nutrition trials with hard clinical endpoints, where participants
need to be followed for many years for such events to be observed. As some of the outcomes of
this review constituted secondary outcomes for some studies, these might not have been sufficiently
powered to provide valid conclusions. Further, although methods of assessment of compliance to the
dietary treatments were documented in the majority of included papers, actual reporting of compliance
findings was limited for most studies, and not deemed sufficient to delineate which intervention
components may have contributed to the observed effects. Further, although risk of bias across studies
was similar to that reported in earlier meta-analyses of complex interventions [23], several sources of
bias identified as having unclear or high risk may affect our findings’ interpretation.
A further limitation is that significant and substantial between-study heterogeneity was observed
for most MetSyn components and risk factors, particularly for outcomes with a large number of
studies included. We accounted for this by applying random-effects models to account for variations
across studies, and further assessed sources of heterogeneity by conducting subgroup analyses
and meta-regressions, when the number of studies per health outcome allowed [26]. This level of
heterogeneity, despite being similar to earlier meta-analyses of complex MD interventions [12,113],
was not considerably explained by the subgroup analyses and meta-regressions, which creates
uncertainty as to what the true effect of the MD might be, and limits the interpretation and
generalizabilityof the findings. Other participant, study, or intervention characteristics, such as
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recruitment methods, intervention intensity, and delivery methods or sociocultural contexts, might have
contributed to the heterogeneity across studies, but these are challenging to discern from published
papers. Despite these high levels of heterogeneity for some outcomes, we proceeded with the
meta-analysis, as this allowed us to compare findings across studies and examine the consistency of
observed effects, in addition to facilitating the interpretation of results, which would be challenging
without the pooled findings. As such, even though our results should be interpreted with caution,
the consistent direction of effect that was observed in the majority of outcomes points towards the
benefits of the MD.
5. Conclusions
This review of controlled trials provides evidence that the MD beneficially affects several outcomes
implicated in metabolic health, including MetSyn components and several metabolic risk factors,
in addition to incidence of CVD and stroke. Nevertheless, pooled findings should be interpreted
with caution due to the substantial between-study heterogeneity found for most analyses and the
small number of studies for some outcomes. Trials with appropriate comparator groups and more
homogeneous designs are needed to help confirm whether the MD results in greater health benefits if
combined with other intervention components, such as energy restriction, or if foods are provided
to participants alongside advice to follow the diet, over and above those acquired separately by MD
advice. More studies are also needed in non-Mediterranean populations, such as the United States of
America, Northern Europe, and Australasia, to establish the feasibility and acceptability of the MD in
these regions. Finally, more high-quality and adequately powered trials are needed to provide robust
evidence on the effect of the MD on MetSyn incidence, other related comorbidities, such as NAFLD,
and use of pharmacotherapy for MetSyn components and comorbidities, and delineate the biological
mechanisms responsible for any health benefits. This would help establish whether the MD should
form part of dietary guidelines globally, be widely promoted by healthcare practitioners and adopted
by the general population for metabolic health benefits. Nevertheless, given the high health and
economic burden of the MetSyn, its comorbidities, and the resulting need for pharmacotherapy to treat
these, in conjunction with the consistent direction of beneficial effects observed in the current report,
practitioners should not abstain from recommendingthe MD as a whole, and its food components, in
intakes illustrated in the updated Mediterranean Diet Pyramid [10], to their adult patients for a wide
range of metabolic health benefits.
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